Labcorp — Feb 17, 2026 release

16.44 vs $14.57 ◦ Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billion • Provided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: ◦ Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4% ◦ Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9% ◦ Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8% • Expanded partnerships with health systems and regional/local laboratories by signing or closing 13 transactions in 2025 • Advanced leadership in specialty testing, launching more than 130 innovative new tests in 2025, including in oncology, women’s health, neurology and autoimmune • Announced strategic investment to build a modern, state-of-the-art 500,000 square foot Central Laboratory facility to address growth in demand BURLINGTON, N.C., February 17, 2026 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter and full year ended December 31, 2025, and provided 2026 guidance. “In 2025, Labcorp grew revenue over 7% and delivered double-digit adjusted EPS growth, margin expansion and strong free cash flow. Performance was driven by continued strength in our Diagnostics and Central Laboratory businesses,” said Adam Schechter, Chairman and CEO of Labcorp. “We made significant progress across our strategic priorities, and we beg